Back to top
more

Virtus LifeSci Biotech Clinical Trials ETF: (BBC)

(Delayed Data from NYSE) As of Apr 25, 2025 03:55 PM ET

$18.15 USD

18.15
59,752

-0.51 (-2.73%)

Volume: 59,752

Zacks ETF Rank

This is our ETF rating system that serves as a timeliness indicator for ETFs over the next 6 months:

Zacks Rank Definition
1 Strong Buy
2 Buy
3 Hold
4 Sell
5 Strong Sell

See all the Top Ranked ETFs here - The complete list of all the top ranked ETFs

3 - Hold of 5     3    

After-Market: $18.35 +0.20 (1.10 %) 7:58 PM ET

ETF Quote Details

Previous Close 18.66
Open 18.44
Bid 17.91
Ask 18.77
Day Low-High 18.14-18.55
52wk Low-High 13.42-31.65
Volume 59,752
NAV (month end) 17.61
Premium (+)/Discount (-) (month end)+1.05

Zacks Premium Research for BBC

Zacks ETF Rank

This is our ETF rating system that serves as a timeliness indicator for ETFs over the next 6 months:

Zacks Rank Definition
1 Strong Buy
2 Buy
3 Hold
4 Sell
5 Strong Sell

See all the Top Ranked ETFs here - The complete list of all the top ranked ETFs

 Hold 3
ETF Risk

Zacks proprietary quantitative models divide each set of ETFs following a similar investment strategy (style box/industry/asset class) into three risk categories- High, Medium, and Low. The aim of our models is to select the best ETFs within each risk category, so that investors can pick an ETF that matches their particular risk preference in order to better achieve their investment goals.

High
ETF Snapshot

ETF Expense Ratio

Expense Ratio 0.79%
Dividend (Yield) $0.24 (1.31%)
Issuer VIRTUS INVESTMENT PARTNERS INC

Benchmark for BBC

LIFESCI BIOTECH CLINICAL TRIALS INDEX

The LifeSci Biotechnology Clinical Trials Index is an equal weighted index that is designed to measure the equity market performance of the common stock of U.S. exchange-listed biotechnology companies with a primary product offering that is in a Phase 1, Phase 2 or Phase 3 clinical trial stage of development.

Fund Summary for BBC

VIRTUS LIFESCI BIOTECH CLINCL TRIALS ETF

The Virtus LifeSci Biotech Clinical Trials ETF seeks investment results that correspond, before fees and expenses, to the price and yield performance of the LifeSci Biotechnology Clinical Trials Index.